An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease
- Registration Number
- NCT02271347
- Lead Sponsor
- Chimerix
- Brief Summary
The purpose of this study is to assess the safety and tolerability of Brincidofovir (BCV) when administered as an initial 200mg dose followed by 100mg twice weekly (BIW) for a total of 5 doses.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Positive for Ebola virus RNA in plasma
- Subject must be able to ingest, absorb, and tolerate oral medication
- Subject must be willing to use adequate contraception during their participation
Exclusion Criteria
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description CMX001 CMX001 CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
- Primary Outcome Measures
Name Time Method Number of Participants with Adverse Events as a Measure of Safety and Tolerability. 4 weeks
- Secondary Outcome Measures
Name Time Method